Gilead Sciences: 13.4% Upside Predicted 01/20/26
/
RSS Feed
Gilead Sciences: 13.4% Upside Predicted 01/20/26
Key Stories:
- US Financial 15 Split Corp, a fund investing in a portfolio of 15 U.S. financial services companies including heavyweights like American Express, Bank of America, and Citigroup, has declared its latest monthly distribution. Shareholders will receive $0.07283 for each Preferred share. This translates to an impressive 10.00% annually, calculated based on the previous month’s net asset value. These distributions are set to be paid out on February 10, 2026, to shareholders on record as of January 30, 2026, offering a consistent income stream for investors focused on the financial sector. Read more
- Shifting gears to pharmaceuticals, biotech giant Gilead Sciences is currently being eyed as undervalued by analysts, receiving a ‘Buy’ rating. A discounted cash flow analysis sets a target price of $141 for the stock, suggesting a significant 13.4% upside from current levels. The optimistic outlook stems from the company’s strong margin expansion and robust cash flow generation. Analysts believe this paints a picture of a healthy balance sheet that investors might be overlooking, suggesting potential for growth for those looking into the biotech space. Read more
- Finally, we turn our attention to the energy sector, where Chris Womack, the chief executive officer of utility giant Southern Co., shared some interesting insights from the World Economic Forum in Davos. Womack forecasts a substantial increase in electricity demand, projecting growth of as much as 8% to 10% in the coming years. He attributes this to what he describes as “incredible demand and opportunity” on the horizon. Additionally, he weighed in positively on President Trump’s proposal to directly auction energy to some technology companies, calling it a “good idea.” This points to significant potential demand for utilities and energy providers moving forward. Read more
Keywords: American Express, Bank of America, Buy rating, Citigroup, DCF, GILD, PJM plan, Preferred shares, SO, Trump, USF, World Economic Forum, biotech, cash flow, dividend, electricity demand, energy sector, financial services, income stream, margin expansion, target price, undervalued, utility